×

Cesca Therapeutics Invited to Present at Aegis Capital Growth Conference, and the Stem Cell Meeting on the Mesa Conference

RANCHO CORDOVA, Calif., Oct. 1, 2015 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, announced today that the Company will present at the 2015 Aegis Capital Growth Conference, and the 2015 Stem Cell Meeting on the Mesa on Thursday, October 8, 2015.

2015 Aegis Capital Growth Conference

The Aegis Capital Healthcare & Technology Conference provides a forum to introduce small-cap companies in the life sciences and technology sectors to the investment community. This invitation-only event attracts a wide array of research analysts, fund managers, qualified high net worth individuals and financial advisors seeking compelling ideas for their portfolios. The conference is hosted by Aegis Capital, which is a leader in providing capital raising and financial advisory services for emerging growth companies.

The following are specific details regarding Cesca's presentation at the conference:

  • Date and Time: October 8, 2015, 3:30pm PT
  • Location: The Encore at Wynn Las Vegas, Las Vegas
  • Presenter: Robin Stracey, Chief Executive Officer
  • Topic: Corporate Presentation

The Company's presentation can be accessed on its website. Please go to http://cescatherapeutics.com/investors/webcasts-calls/

2015 Stem Cell Meeting on the Mesa

This conference is the sector's premier forum bringing together senior executives and top decision makers in the industry within the scientific community with the shared goal of advancing and translating cutting-edge research into revolutionary treatments and cures.

Co-hosted by the Alliance for Regenerative Medicine (ARM), the California Institute for Regenerative Medicine (CIRM) and the Sanford Consortium for Regenerative Medicine, the 2015 Stem Cell Meeting on the Mesa is a three-day conference featuring program's two-day Partnering Forum, a Public Forum lecture and a full-day Scientific Symposium.

Stem Cell Meeting on the Mesa is expected to attract nearly 800 attendees, including leading cell therapy, gene therapy and tissue engineering companies, large pharma and biotech, industry investors and major academic research institutions.

The following are specific details regarding Cesca's presentation at the conference:

  • Date and Time: October 8, 2015, 2:15pm PT
  • Location: Estancia La Jolla Hotel & Spa, 9700 North Torrey Pines Road, La Jolla, CA 92037
  • Presenter: Ken Harris
  • Topic: Corporate Presentation

A live video webcast of all company presentations will be available at: http://stemcellmeetingonthemesa.com/webcast/ and will also be published on ARM's website shortly after the event.

About Cesca Therapeutics Inc.

Cesca Therapeutics Inc. (www.cescatherapeutics.com) is engaged in the research, development and commercialization of autologous cell-based therapeutics for use in regenerative medicine. The Company is a leader in the development and manufacture of automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapy products. These include:

  • SurgWerks™; proprietary stem cell therapy point-of-care kits for the treatment of vascular and orthopedic indications that integrate the following indication specific elements:

-- Cell harvesting

-- Cell processing and selection

-- Cell diagnostics

-- Cell delivery

  • CellWerksTM; an integrated system which includes a protocol, disposables and equipment for intra-laboratory use in treatment of oncological and hematological disorders.
  • The AutoXpress® (AXP); a proprietary automated device, along with companion sterile blood processing disposables, for the harvesting of stem cells from cord blood.
  • The MarrowXpress (MXP); a device and disposable system based on the AutoXpress platform for the isolation and concentration of stem cells from bone marrow. Self-powered and microprocessor-controlled, the MXP contains flow control and optical sensors and concentrates white blood cells from bone marrow to a user- defined volume in 40 minutes while retaining over 90% of mononuclear cells (MNCs).
  • The BioArchive® System; an automated cryogenic device, used by cord blood stem cell banks in more than 30 countries, for cryopreservation and archiving of cord blood stem cell units for transplant.

Forward Looking Statement

The statements contained herein may include statements of future expectations and other forward looking statements that are based on management's current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements, including our ability to initiate and prosecute the pivotal CLIRST III trial, our ability to obtain efficacy consistent with prior CLI studies, continued FDA approval, Medicare reimbursement approval, timing of the Company's future submission of IDE, PMA and/or Medicare reimbursement applications, or amendments to such applications, and outcomes from such submissions. Further, clinical trial outcomes are not predictable, and results may vary from the Company's expectations, including the start of any such clinical trials, patient follow up issues, and costs associated with such trials. Further description of other risks that could cause actual events to differ from the outcomes predicted by Cesca Therapeutics' forward-looking statements is set forth under the caption "Risk Factors" in Cesca Therapeutics' annual report on Form 10-K and other reports it files with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements. Contact: Cesca Therapeutics Inc. http://www.cescatherapeutics.com. Cesca may, at its discretion, choose to publish on-going interim notifications, requests for further information as received from the FDA, Medicare or equivalent foreign agencies, but as a general policy only makes announcements regarding material or significant information, such as filing of applications, approvals, initiation of studies, and conclusions.

CONTACT: Cesca Therapeutics Inc. http://www.cescatherapeutics.com Investor Contact: Kirin Smith, PCG Advisory Group 646-863-6519, or ir@cescatherapeutics.com Media Contact: Sean Leous, PCG Advisory Group 646-863-8998 or sleous@pcgadvisory.com

Source:Cesca Therapeutics Inc.